Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Current Report · Items 5.03, 5.07, 9.01 · 8-K

Context Therapeutics Inc.

CNTXNASDAQEQUITYCurrent

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year · Submission of Matters to a Vote of Security Holders

Item 5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. On June 24, 2026, Context Therapeutics Inc. (the “Company”) held its Annual Meeting of Stockholders (the “Meeting”).…

Filed Jun 26, 2026Accepted Jun 26, 2026, 4:07 PM EDTCIK 1842952Accession 0001628280-26-045744
Share

Company context

Current securities

Recent company filings

  1. Regulation FD Disclosure · Other EventsNov 10, 2026
  2. 10-Q filingNov 10, 2026
  3. SCHEDULE 13G/A - filed by Blue Owl Capital Holdings LP regarding Context Therapeutics Inc.Aug 12, 2026
  4. Regulation FD DisclosureAug 5, 2026
  5. 10-Q filingAug 5, 2026

Registered securities in this filing

Context Therapeutics Inc. · 8-K · Filed 2026-06-26

As filed in this accession. Current/historical status below comes from the governed listing record; the cover itself remains exact to this filing.

Common Stock

Symbol
CNTX
Exchange
NASDAQ
Classification
COMMON
Status
Current
Filing context

Context: c-1

Dimensions: Not supplied

Accession 000162828026045744 · 1 registered-security cover member

Read the exact SEC filing ↗

Disclosure sections

Items 5.03, 5.07, 9.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 5.03Item 5.03 - Amendments to Articles/Bylaws
Item 5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. On June 24, 2026, Context Therapeutics Inc. (the “Company”) held its Annual Meeting of Stockholders (the “Meeting”). At the Meeting, the Company’s stockholders approved, among other things, an amendment to the Company's Amended and Restated Certificate of Incorporation (the "Certificate") to increase the number of authorized shares of common stock from 200,000,000 to 300,000,000. A copy of the Certificate of Amendment to the Certificate to increase the number of authorized shares of common stock from 200,000,000 to 300,000,000, as filed with the Secretary of State of the State of Delaware on June 24, 2026, is attached as Exhibit 3.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Item 5.07Item 5.07 - Submission of Matters to Vote
Item 5.07 Submission of Matters to a Vote of Security Holders. As of April 27, 2026, the record date for the Meeting, there were 91,879,177 shares of common stock issued and outstanding and entitled to vote on the proposals presented at the Meeting, of which 72,830,990, or approximately 79.27%, were present in person or represented by proxy, which constituted a quorum. The holders of shares of the Company’s common stock are entitled to one vote for each share held. Set forth below are the final voting results for each of the proposals submitted to a vote of the Company’s stockholders at the Meeting. Proposal 1. Election of Directors The Company’s stockholders elected the following seven director nominees to the Company’s Board of Directors, each to serve until the Company’s 2027 Annual Meeting of Stockholders or until his or her successor is elected and qualified or until his or her earlier death, resignation or removal. For Withhold Broker Non-Votes ────────────────────────────────────────────────────────────────────────────── Dr. Philip Kantoff 63,340,793 50,310 9,439,887 Martin Lehr 63,369,775 21,328 9,439,887 Andy Pasternak 63,376,712 14,391 9,439,887 Dr. Karen Smith 63,346,225 44,878 9,439,887 Jennifer Evans Stacey 61,370,391 2,020,712 9,439,887 Dr. Luke Walker 63,376,732 14,371 9,439,887 Linda West 63,339,289 51,814 9,439,887 Proposal 2. Ratification of Selection of Independent Registered Public Accounting Firm The Company’s stockholders ratified the selection of CohnReznick LLP as the Company’s independent registered public accounting firm for its fiscal year ending December 31, 2026. The voting on this proposal is set forth below: For Against Abstentions Broker Non-Votes ─────────────────────────────────────────────────────────────────────────────────────────────────────── Ratification of CohnReznick LLP 72,762,152 65,395 3,443 --- Proposal 3. Approval of Proposed Amendment to the Certificate The Company’s stockholders approved an amendment to the Certificate to increase the number of authorized shares of the Company’s common stock from 200,000,000 to 300,000,000. The voting on this proposal is set forth below: For Against Abstentions Broker Non-Votes ────────────────────────────────────────────────────────────────────────────────────────────────── Amendment to Certificate 71,752,165 1,050,867 27,958 --- Proposal 4. Approval of Meeting Adjournment The Company’s stockholders approved one or more adjournments of the Meeting to a later date or dates if necessary or appropriate to solicit additional proxies if there are insufficient votes to approve Proposal 3 at the time of the Meeting. The voting on this proposal is set forth below: For Against Abstentions Broker Non-Votes ─────────────────────────────────────────────────────────────────────────────────────────── Meeting Adjournment 71,827,930 980,425 22,635 --- Adjournment of the Meeting was not necessary or appropriate because there were sufficient votes in favor of Proposal 3.

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.